Exploring Patients Perspectives on the use of SGLT2 inhibitors for adjunct-to-insulin treatments in patients living with Type 1 Diabetes
Summary
We are looking for people living with type 1 diabetes (T1D) to take part in a one-time interview. We want to know what you think about a new class of oral medications in use in addition to standard insulin treatment. Patients using Sodium-glucose co-transporter-2 (SGLT2) inhibitors may potentially see benefits such as lowered glucose, blood pressure, and body weight, and decreased risk of kidney failure and heart disease, but also have an increased risk of diabetic ketoacidosis (DKA).
We would like to know from your perspective when do the perceived benefits outweigh the risk of DKA? We want to understand when and why patients find SGLT2 inhibitor use acceptable. In the interview, we will ask questions to learn about all the factors people living with T1D take into consideration when making these decisions. Please participate to share your thoughts on this important issue.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 99
Inclusion criteria:
1) Adult (≥18 years of age)
2) Type 1 Diabetes (≥5 years since diagnosis)
3) Able to participate in an interview in English
Exclusion criteria:
1) Type 1 Diabetes (<5 years since diagnosis)
2) On dialysis or wait listed for kidney transplant
3) Unable to participate in an interview due to language constraints or other reason
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Research Coordinator Pamela LeBlanc leblancp@ucalgary.ca
Principal investigator:
David Campbell
Clinical trial:
No
REB-ID:
REB23-1024